Louise M Thoma, Joel R Thompson, Jason Sharpe, Beth Jonas, Patti Katz, Kelli Allen
{"title":"Preserving Valued Activities in Life for Adults With Rheumatoid Arthritis: Development and Pre-Testing Refinement of the PREVAIL Model of Care.","authors":"Louise M Thoma, Joel R Thompson, Jason Sharpe, Beth Jonas, Patti Katz, Kelli Allen","doi":"10.1002/acr2.90130","DOIUrl":"10.1002/acr2.90130","url":null,"abstract":"<p><strong>Objective: </strong>Rehabilitation is rarely integrated into routine rheumatology care, despite high rates of functional limitation in adults with rheumatoid arthritis (RA). The Preserving Valued Activities in Life (PREVAIL) model of care proposes a function-focused screening survey administered during routine rheumatology visits to guide referrals to rehabilitation and facilitate integration into standard RA care. This study aimed to assess the perceived feasibility and acceptability of the PREVAIL model and inform modifications for pilot testing.</p><p><strong>Methods: </strong>We used a multimethod approach including (1) a cross-sectional survey of 309 adults with RA to assess the feasibility and validity of a proposed screening tool to identify functional limitations for referral and (2) semistructured interviews with 24 adults with RA, 6 rheumatology clinicians, and 6 physical therapists to evaluate the perceived acceptability and feasibility of the PREVAIL model of care.</p><p><strong>Results: </strong>The proposed screening tool demonstrated moderate correlations with established measures of functional status and disease activity but identified 90% of participants for rehabilitation referral based on proposed disability risk criteria, necessitating refinement. Interview data revealed broad support for the PREVAIL model across key vested parties. Participants emphasized the value of proactively addressing function, identified patient and clinician knowledge gaps regarding rehabilitation, and highlighted the model's potential to enhance patient-clinician communication. Modifications to improve feasibility included remote survey completion, educational materials for key vested parties, and an interim physical therapy consultation call to better prioritize referrals.</p><p><strong>Conclusion: </strong>The PREVAIL model of care was perceived to be both feasible and acceptable. Study findings directly inform refinements to support real-world implementation in a pilot clinical trial.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"8 8","pages":"e90130"},"PeriodicalIF":2.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13451645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148690531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exploring the Shared Genetic Basis of Age at Menopause and Osteoarthritis.","authors":"Bingru Luo, Lili Huang, Jing Zhou, Panpan Long","doi":"10.1002/acr2.90087","DOIUrl":"10.1002/acr2.90087","url":null,"abstract":"<p><strong>Objective: </strong>The relationship between age at menopause and osteoarthritis (OA) remains unclear.</p><p><strong>Methods: </strong>The genetic commonalities between age at menopause and OA were investigated using data from publicly accessible genome-wide association studies. A variety of methods were employed in this exploration, such as linkage disequilibrium score regression (LDSC), high-definition likelihood, LAVA, pleiotropic analysis under composite null hypothesis, and summary-databased Mendelian randomization. Additionally, causal relationships were probed through the application of Mendelian randomization techniques.</p><p><strong>Results: </strong>A significant negative genetic correlation was identified between age at menopause and OA, with a genetic correlation coefficient of -0.115 and a P value of 1.79 × 10<sup>-6</sup>, as determined by LDSC. Then, a number of single nucleotide polymorphisms associated with both OA and the age at menopause were identified to exhibit pleiotropic effects. Age at menopause had a causal effect on OA. In addition, six potentially functional genes, C7orf73, RP11-148O21.2, BLK, PAM16, MAPK3, and DBF4B, have been identified to exhibit associations with both age at menopause and OA.</p><p><strong>Conclusion: </strong>This study's results provide a deeper comprehension of the genetic underpinnings and complex interplay between age at menopause and OA. It contributes novel perspectives for the discovery of shared genetic-based therapeutic targets, highlighting the value of understanding their common genetic framework for developing future treatments.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"8 7","pages":"e90087"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13316948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148355173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Isabel Silva, Jasper Dayanan, Alexandra Nigro, Capriana Jiang, Ma Georgina Erfe, Trixie Rivera, Saakshi Khattri
{"title":"International Myositis Assessment and Clinical Studies Guidelines for Risk-Based Cancer Screening: An External Validation in Patients With Dermatomyositis Seen at a Metropolitan Academic Center.","authors":"Isabel Silva, Jasper Dayanan, Alexandra Nigro, Capriana Jiang, Ma Georgina Erfe, Trixie Rivera, Saakshi Khattri","doi":"10.1002/acr2.90101","DOIUrl":"10.1002/acr2.90101","url":null,"abstract":"<p><strong>Objective: </strong>Dermatomyositis (DM) is an idiopathic inflammatory myopathy (IIM) characterized by muscle weakness, skin findings, and increased malignancy risk. Cancer risk is greatest in the three years before or after DM onset, termed paraneoplastic DM. The International Myositis Assessment and Clinical Studies Group (IMACS) set forth evidence-based guidelines for risk stratification and cancer screenings for newly diagnosed patients with IIM.</p><p><strong>Methods: </strong>We retrospectively reviewed the records of 413 patients with a known diagnosis of DM or clinically amyopathic DM at the Mount Sinai Health System (2019-2024). Demographics, clinical findings, laboratory results, myositis autoantibody panels, and cancer screening or diagnosis data were collected.</p><p><strong>Results: </strong>Among the 413 patients with DM, 6.5% (n = 27) had paraneoplastic DM. The proportion of paraneoplastic disease was highest in the high-risk group (8.8%), compared to intermediate- (5.1%) and low-risk (2.5%) groups. 70.4% of patients with paraneoplastic DM were categorized as high risk, compared to 51% of nonparaneoplastic patients. Among the intermediate-risk patients, most patients were diagnosed with cancer more than one year after DM diagnosis. Age ≥40 at DM diagnosis was statistically significant for an increased risk of paraneoplastic DM (P = 0.001). The most common paraneoplastic malignancies were breast cancer and lung cancer. One-third of patients with paraneoplastic DM were diagnosed with cancer within three years preceding DM diagnosis.</p><p><strong>Conclusion: </strong>The IMACS screening guidelines and risk stratification showed moderate sensitivity for identifying paraneoplastic DM, helping to identify a majority of patients at the highest risk for malignancy leading to more targeted and risk-based screening.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"8 7","pages":"e90101"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13322779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148371216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alberto Sulli, Elvis Hysa, Paolo Clini, Emanuele Gotelli, Tamara Vojinovic, Carmen Pizzorni, Ali Jaffal, Sabrina Paolino, Rosanna Campitiello, Vanessa Smith, Maurizio Cutolo
{"title":"An Engineered Glove for the Objective Assessment of Hand Dexterity in Patients With Systemic Sclerosis.","authors":"Alberto Sulli, Elvis Hysa, Paolo Clini, Emanuele Gotelli, Tamara Vojinovic, Carmen Pizzorni, Ali Jaffal, Sabrina Paolino, Rosanna Campitiello, Vanessa Smith, Maurizio Cutolo","doi":"10.1002/acr2.90082","DOIUrl":"10.1002/acr2.90082","url":null,"abstract":"<p><strong>Objective: </strong>Hand disability is a major musculoskeletal functional impairment in systemic sclerosis (SSc), but its objective assessment remains challenging. The validated Hand Test System (HTS) engineered glove has provided quantitative dexterity data in rheumatic diseases. The primary objective was to evaluate the applicability of the HTS glove in patients with SSc by comparing its parameters (touch duration [TD], intertapping interval [ITI], and movement rate [MR]) with healthy controls (HCs). The assumptions were that HTS parameters would be significantly impaired in patients with SSc and would correlate with clinical, imaging, and patient-reported outcome measures (PROMs).</p><p><strong>Methods: </strong>A cross-sectional study was conducted enrolling 25 patients with SSc (fulfilling 2013 American College of Rheumatology/EULAR criteria) and 25 matched HCs. The main outcome variables were the HTS glove parameters. All participants also underwent grip strength measurement and an assessment of PROMs (Scleroderma Health Assessment Questionnaire and Duruöz Hand Index), together with a performance-based evaluation of hand mobility using the Hand Mobility in Scleroderma test. Clinical and imaging data were collected for patients with SSc including the modified Rodnan skin score (mRSS) and high-frequency skin ultrasonography (HFSU) to measure hand and total body dermal thickness.</p><p><strong>Results: </strong>Patients with SSc performed finger movements significantly more slowly and less efficiently than HCs, demonstrated by prolonged mean TD and ITI and reduced MR (P < 0.05 for all). In patients with SSc, HTS parameters significantly correlated with poorer PROMs (0.39 < r < 0.65, all P < 0.01 for all). Notably, both mean TD and ITI directly correlated with the mRSS (0.40 < r < 0.48, all P < 0.05). Furthermore, the mean TD showed a significant direct correlation with HFSU-measured dermal thickness of the dorsum of the hands and with total body dermal thickness (P < 0.05 for all). No significant differences in HTS parameters were detected based on nailfold videocapillaroscopy findings or organ involvement.</p><p><strong>Conclusion: </strong>The HTS glove provides objective measures of the impaired hand dexterity in SSc. The significant correlations between HTS parameters, PROMs, mRSS, and HFSU-measured dermal thickness suggest a significant relationship between skin fibrosis and functional hand disability. The HTS glove seems a promising tool for objectively monitoring SSc hand outcomes, and studies to explore its utility in monitoring therapeutic responses are in progression.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"8 7","pages":"e90082"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13329684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148378464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"In Vitro Fertilization is Essential Healthcare for Patients With Rheumatic Disease.","authors":"Amanda Moyer, Catherine A Sims, Rosalind Ramsey-Goldman, Solmaz Chamanara, Cuoghi Edens","doi":"10.1002/acr2.90090","DOIUrl":"10.1002/acr2.90090","url":null,"abstract":"<p><p>Infertility presents a profound physical, emotional, and financial burden, particularly for rheumatology patients who often face substantial barriers to family building. The 2024 Alabama Supreme Court ruling in LePage v. Center for Reproductive Medicine equating embryo destruction with wrongful death introduced new legal uncertainties, sparking concerns about access to in vitro fertilization (IVF) and reproductive health services across the United States. Although Alabama's subsequent legislative action granted temporary protections for fertility providers, the broader implications of embryo personhood laws remain unresolved. For patients with rheumatic diseases, timely access to assisted reproductive technology (ART) is essential. However, barriers such as limited ART awareness, concerns about safety and success, social and religious stigma, and financial and legal restrictions disproportionately impact this population. The consequences of restrictive policies extend beyond females, affecting men and same-sex couples who rely on IVF to expand their families. Infertility is a recognized medical condition, and restricting ART access is medically and ethically indefensible. As physicians, researchers, and advocates, we must actively oppose legal decisions and policies that limit ART availability, including insurance restrictions, discriminatory practices, and embryo personhood legislation. Protecting and expanding ART access is critical-not only for rheumatology patients but for the one in eight couples and one in four physicians affected by infertility. Ensuring equitable, evidence-based reproductive care is imperative to safeguarding the right to family building for all.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"8 7","pages":"e90090"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13307328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148341449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Loqmane Seridi, Eugene Myshkin, Erika Noss, Sheng Gao, Julio Molineros, Carolyn Cuff, Dawn Waterworth, Matthew J Loza
{"title":"Reproducible Molecular Subtypes in Systemic Lupus Erythematosus Are Associated With Disease Activity, Serology, and Distinct Trajectories Over Time.","authors":"Loqmane Seridi, Eugene Myshkin, Erika Noss, Sheng Gao, Julio Molineros, Carolyn Cuff, Dawn Waterworth, Matthew J Loza","doi":"10.1002/acr2.90083","DOIUrl":"10.1002/acr2.90083","url":null,"abstract":"<p><strong>Objective: </strong>Systemic lupus erythematosus (SLE) is biologically heterogeneous, motivating development of reproducible molecular subtypes that can track change over time. The aim of this study was to establish a reproducible molecular stratification of SLE across cohorts and platforms and connect the resulting subtypes to clinical activity, serology, and serum proteomics.</p><p><strong>Methods: </strong>We computed Gene Set Variation Analysis scores for eight immune gene modules from baseline transcriptomes (ILLUMINATE whole-blood microarray [N = 1,756], LOTUS whole-blood RNA sequencing [RNA-seq; N = 585], and Genuity peripheral blood mononuclear cell (PBMC) RNA-seq [N = 812]). We clustered ILLUMINATE patients (K = 2-8) and selected K = 6, then used a random forest classifier to assign subtypes in LOTUS and Genuity. We analyzed serum proteomics (SomaScan in LOTUS; Olink in Genuity), assessed glucocorticoid associations with neutrophil modules, and quantified baseline to week 24 stability in LOTUS.</p><p><strong>Results: </strong>Six molecular subtypes replicated across cohorts and corresponded to different levels of disease activity and serology (P < 0.001). Proteomic patterns converged with transcriptomics, with concordant differential proteins across Olink and SomaScan among shared targets. Neutrophils were a key axis: one neutrophil module tracked glucocorticoid use, whereas a second was glucocorticoid independent. In LOTUS, subtype assignments were mostly stable to week 24; when patients moved, transitions were nonrandom, occurred between adjacent subtypes, and were similar in the placebo group.</p><p><strong>Conclusion: </strong>We demonstrated reproducible SLE molecular subtypes (interferon, plasmablast/B cell, neutrophil) supported by independent proteomics. In LOTUS, subtypes were largely stable through week 24. When patients changed subtypes, transitions followed preferential trajectories, supporting longitudinal tracking and trial design utility.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"8 7","pages":"e90083"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13332139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148383355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Synovial Fluid Cell Profiling Identifies Distinct Inflammatory Phenotypes in Late-Onset Rheumatoid Arthritis and Polymyalgia Rheumatica.","authors":"Shigeru Tanaka, Takahiro Sugiyama, Shuhei Kameda, Tatsuro Takahashi, Masahiro Yasui, Yuki Hayashi, Tomoaki Ida, Yuhi Yoshida, Soichiro Kubota, Takashi Ito, Takahiro Kageyama, Daiki Nakagomi, Kei Ikeda, Shin-Ichiro Kagami, Hiroshi Nakajima","doi":"10.1002/acr2.90086","DOIUrl":"10.1002/acr2.90086","url":null,"abstract":"<p><strong>Objective: </strong>Late-onset rheumatoid arthritis (LORA) and polymyalgia rheumatica (PMR) can be difficult to distinguish, particularly in anti-citrullinated protein antibody (ACPA)-negative patients. We aimed to characterize synovial fluid immune cell profiles in ACPA-positive LORA, ACPA-negative LORA, and PMR, and to explore biologically informed patient stratification using an unbiased approach.</p><p><strong>Methods: </strong>Synovial fluid was aspirated from inflamed periarticular synovial structures of the shoulder, including the subacromial and subdeltoid bursae and the tendon sheath of the long head of the biceps, in 21 patients with ACPA-positive LORA (n = 5), ACPA-negative LORA (n = 8), or PMR (n = 8). Immune cell composition was analyzed by mass cytometry. Principal component analysis and hierarchical clustering were performed to stratify patients.</p><p><strong>Results: </strong>ACPA-positive LORA demonstrated neutrophil predominance compared with PMR. In contrast, PMR demonstrated a neutrophil-poor profile characterized by higher proportions of T cells and natural killer cells. ACPA-negative LORA showed substantial heterogeneity, with individual patients displaying either neutrophil-rich or neutrophil-poor patterns. Unsupervised clustering of mass cytometry data segregated ACPA-positive LORA and PMR into distinct clusters, whereas ACPA-negative LORA cases were distributed across both clusters.</p><p><strong>Conclusion: </strong>This exploratory study suggests that late-onset inflammatory arthritis comprises at least two distinct synovial inflammatory phenotypes that may not fully correspond to current clinical diagnoses. ACPA-negative LORA appears to represent a heterogeneous condition encompassing these distinct states of inflammation. Synovial fluid immunophenotyping may complement conventional classification and support biologically informed therapeutic stratification.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"8 7","pages":"e90086"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13309291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148341444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lance A Riley, Luke E Springer, Sandra Paola Cárdenas-García, Tatiana Simon, Farshid Guilak, Christine T N Pham, Erik D Herzog
{"title":"Local Circadian Clocks Are Desynchronized From the Central Circadian Pacemaker in a Mouse Model of Inflammatory Arthritis.","authors":"Lance A Riley, Luke E Springer, Sandra Paola Cárdenas-García, Tatiana Simon, Farshid Guilak, Christine T N Pham, Erik D Herzog","doi":"10.1002/acr2.90112","DOIUrl":"10.1002/acr2.90112","url":null,"abstract":"<p><strong>Objective: </strong>Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting joints marked by daily and intermittent surges in inflammatory cytokine levels that result in \"flares\" of disease activity. Because circadian proteins regulate inflammatory responses in arthritis, continuous behavioral- and tissue-level monitoring may clarify therapeutic dynamics. Using the K/BxN serum transfer arthritis (STA) mouse model, we tested whether locomotor activity and circadian clock gene expression track RA progression from onset through symptom resolution.</p><p><strong>Methods: </strong>C57BL/6NJ and PER2::luciferase mice (8-10 weeks) received 180 μL K/BxN serum via retroorbital injection. Uninjected littermates served as controls. We measured daily ankle thickness and continuously monitored open-field locomotion from singly housed mice, a subset of which received dexamethasone (DEX) at dusk daily for 6 days. PER2::luciferase bioluminescence from paw, suprachiasmatic nuclei (SCNs), and femoral heads explants from mice treated with or without DEX were compared during STA.</p><p><strong>Results: </strong>Total daily locomotion decreased alongside ankle swelling approximately 2 days following K/BxN STA. STA altered the timing of daily PER2 peak expression in arthritic paws but not in the SCN or nonarthritic joints. By day 22, total daily locomotion, ankle thickness, and paw circadian phase had resolved. In vivo DEX reduced circadian phase disruption in arthritic paws, accelerated the resolution of ankle swelling, and increased total daily locomotion without altering locomotor timing.</p><p><strong>Conclusion: </strong>Locomotor activity is a real-time, noninvasive supplement for measuring RA onset and resolution. Altered PER2 expression indicates that local circadian synchrony in arthritic joints is impaired. DEX may aid recovery by resynchronizing circadian rhythms in arthritic tissues.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"8 7","pages":"e90112"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13384909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148537839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}